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Acute respiratory distress syndrome (ARDS) is characterized by the acute development of hypoxemia and bilateral lung infiltrates. 1 Five decades after it was first described and despite lung protective mechanical ventilation strategies 2, 3 and other therapeutic advances such as prone positioning, fluid restrictive therapy and neuromuscular blockade, [4] [5] [6] ARDS is still associated with substantial morbidity and mortality. In a systematic review and meta-analysis that included 89 ARDS studies (53 observational, 36 randomized controlled trials), Phua et al found that the overall pooled weighted mortality was 44.3% (95% confidence interval [CI], 41.8-46.9). 7 In a recent randomized controlled trial (RCT) comparing conservative (SpO 2 88-92%) versus a liberal oxygenation target (≥96%), there were no significant differences in organ dysfunction or mortality between the two groups. These results suggest that patients can survive short periods of relative hypoxemia without significant adverse effect and that hypoxemia may not be the leading cause of mortality in ARDS. 8 On the other hand, hemodynamic instability in the context of ARDS appears to be strongly associated with mortality. 9 One potential mechanism is the dysfunction of the right ventricle (RV) and pulmonary vasculature which is often underappreciated in ARDS. 10 As a result the RV fails to deliver adequate cardiac output to the left sided circulation thus resulting in systemic hypoperfusion and multiple organ dysfunction. 11 The aim of the current review is to discuss the epidemiology of RV dysfunction (RVD) in ARDS and its effect on clinical outcomes, examine the current state of knowledge in the pathophysiology of RV dysfunction, identify gaps and explore the use of novel imaging markers, preventive and therapeutic strategies. Unanswered questions such as effectiveness of 'low lung-stress' ventilation, timing of proning and whether RVD alone should be an indication for proning, the role of extracorporeal life support and natural history of RVD in ARDS survivors will be discussed.

DEFINITIONS
There is a variety of definitions for RV dysfunction (RVD) and failure (RVF) in the literature with the terms being used interchangeably at times. According to the American Society of Echocardiography (ASE) RVD is present when the parameters to quantify RV function are less than the lower value of the normal range: tricuspid annular plane systolic excursion (TAPSE) < 17mm, pulsed Doppler S wave < 9.5cm/sec, RV fractional area change (RVFAC) < 35%, RV ejection fraction (RVEF) < 45%. RVFAC has been used to grade the degree of RVD as mild (25-35%), moderate (18-25%) and severe (<18%). 12, 13 RVF is defined as the inability of the RV to provide adequate blood flow through the pulmonary circulation at normal central venous pressure (CVP). 11 Acute cor pulmonale (ACP) refers to acute dilatation and/or dysfunction of the RV in the context of acute lung disease (eg ARDS) and associated pulmonary vascular dysfunction. 14 ACP is a form of RVD due to acute increase in RV afterload that may lead to RVF and it is defined echocardiographically as septal dyskinesia with a ratio of right ventricular end-diastolic area (RVEDA): left ventricular end-diastolic area (LVEDA) greater than 0.6 (greater than 1 for severe dilatation). In the RV-focused view, RV diameter greater than 41mm at the base and greater than 35mm at midlevel indicates chamber dilatation. 12, 13 In this review we have chosen to use the term 'RVD' instead of 'ACP' as it provides a broader overview of RV pathology in acute pulmonary disease. Assessment of the RV by echocardiography is discussed further in the 'diagnosis' section of this review.
EPIDEMIOLOGY & PROGNOSIS
The reported incidence of RVD in ARDS varies across studies (22% to 50% (Table 1) . [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ) Although there is no robust evidence to support a definitive causal relationship between RVD and mortality in ARDS, it has been shown that RVD has a negative impact on the ARDS course and that severe RVD is associated with increased mortality even during lung protective mechanical ventilation. (Table 1) . 15, 16 There is a need for a consensual definition that reflects the pathophysiology of RVD in the context of ARDS and positive pressure ventilation. This will enable intensive care specialists to identify patients at risk of RVF and implement strategies that may protect the RV.
PATHOPHYSIOLOGY
The RV is responsible for maintaining adequate pulmonary perfusion pressure in order to deliver desaturated mixed venous blood to the respiratory membrane and low systemic venous pressure to prevent organ congestion. The RV is sensitive to changes in afterload because it is anatomically adapted for the generation of low-pressure perfusion.
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Why is the RV failing in ARDS?
RVD is not always associated with an increase in PVR and pulmonary arterial hypertension; it can also be secondary to primary contractile impairment. 11 As a result, low cardiac output (CO) with low mean arterial pressure (MAP) can occur. This can develop into in a vicious cycle, leading to a progressive downward spiral and cardiogenic shock. Patients with an RVD score greater than or equal to 2 had a higher incidence of RVD (19%, 34% and 74% for risk scores of 2, 3 and 4 respectively). The authors recommend that echocardiography should be routinely performed in all ARDS patients with a score > 2. There is lack of data that illustrate sequential relation of any of the above four parameters and severity of RVD. Although the RVD risk score has not yet been validated, it may provide a framework whereby researchers could test the hypothesis that early echocardiography and early implementation of RV protective measures and modification of the above physiological parameters might prevent RV failure and reduce mortality in patients with ARDS.
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Pulmonary Vascular Tone
Elevated pulmonary vascular tone in ARDS could be due to a variety of causes including an imbalance between vasoconstrictors and vasodialators, endothelial injury, arteriolar hypoxic pulmonary vasoconstriction, hypercapnia, acidemia, in situ thrombosis, and muscularization of non-muscularized arteries (pulmonary vascular remodeling). [27] [28] [29] Raised PVR may lead to acute distension of the thin-walled and 'afterload-sensitive' RV resulting in increased oxygen demand, decreased right coronary artery perfusionpressure with reduced oxygen delivery, and tricuspid annular dilatation worsening tricuspid regurgitation and exacerbating volume overload. In addition RV dilatation can cause shifting of the interventricular septum toward the left impeding left ventricular diastolic filling and reducing left ventricular stroke volume, potentially leading to systemic hypotension. This phenomenon is known as 'ventricular interdependence'. 26, 30 It has been shown that pulmonary hypertension may cause RV diastolic dysfunction
which is related to impaired RV mechanical compliance and elevated RV afterload and does improve by reducing the afterload. RV diastolic dysfunction and diastolic ventricular interaction again has not been systematically studied in the context of ARDS. 31 The induces an increase in arterial elastance of the pulmonary vascular system (Ea), whereas the RV system is characterized by the RV elastance (Ees). The ratio Ees/Ea reflects the mechano-energetic aspects of RV-pulmonary vascular coupling which is of paramount importance for cardiovascular performance as it determines RV systolic pressure and RV stroke volume. When Ees/Ea is >1 the system is coupled providing adequate RV performance, stroke work and right coronary blood flow. Hypercapnia-induced increase in RV afterload results in increased Ea and RVD may develop due to uncoupling between the RV and pulmonary circulation. 36, 37 Experimental studies have shown that the buffering of respiratory acidosis is associated with worsening of ARDS. 38 This observation suggests that some of the beneficial anti-inflammatory effects of respiratory acidosis are likely to be due to the acidemia rather than hypercapnia alone. 38 A secondary analysis of the ARDSnet trial data 3 showed that hypercapnic acidemia in ARDS patients who were mechanically ventilated with high tidal volumes (12ml/kg predicted body weight) was associated with reduced 28-day mortality. However, the authors did not examine the effect of hypercapnic acidemia on outcomes at various time-points or over 
Positive Pressure Ventilation
Patients with ARDS typically have considerably reduced functional residual capacity (FRC) and overall lung compliance and a need for an elevated airway pressure to adequately maintain alveolar recruitment. This approach may have deleterious hemodynamic consequences. 41 Positive pressure mechanical ventilation causes an increase in transpulmonary pressure (difference between alveolar and pleural pressure) which worsens non-physiological lung 'stress' and strain (ratio between tidal volume and functional residual capacity). 42 PEEP, tidal volume and lung compliance are the main determinants of lung stress caused by positive pressure invasive ventilation which highlights the need for optimal mechanical ventilation strategies. When transpulmonary pressure exceeds pulmonary venous pressure, it acts as a back-pressure for pulmonary venous return and may increase the RV afterload. 43, 44 Increased PVR occurs at the extremes of lung volume. At low volumes it is caused by the elastic recoil forces of the lung parenchyma causing extra-alveolar vessel and terminal airway collapse leading to alveolar hypoxia and hypoxic pulmonary vasoconstriction. At
high lung volumes increased PVR may occur due to collapse of the alveolar vessels consequent to the tension of the alveolar wall. When PVR is graphically plotted against lung volume, a U-shaped relation is observed with the lowest PVR occurring at the FRC. 45 In ARDS, the distribution of intrapulmonary gas is heterogeneous with collapsed alveoli coexisting with normally aerated lung areas. 46 High PEEP levels can cause hyperinflation of the normally aerated alveoli and intra-alveolar vessel compression leading to high PVR and increased RV afterload. 47 The effect of PEEP on the RV outflow impedance in the context of ARDS has been evaluated by pulmonary artery flow velocity using TEE.
High PEEP (13+4cmH 2 O) was associated with a significant reduction in RV stroke index 47 High plateau pressure (> 27 cmH 2 O) has been associated with a high incidence of RVD (up to 60%) and high mortality rates (up to 42%) in ARDS 48 . Driving pressure (as a surrogate of lung stress) has recently been found to be a ventilation variable that is strongly associated with survival and RVD risk.
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This suggests that it is the stress and strain on the lung that poses risks of abnormal RV physiology. Unfortunately, there is lack of prospective data on whether a 'low pressure' ventilatory approach is 'RV-protective'. Also, it remains unknown as to how much the chest wall contributes to the calculated airway pressures and whether this needs to be taken into account when attempting to risk stratify patients for RVD in ARDS.
Sepsis
In sepsis-related ARDS (pulmonary or extra-pulmonary), RVD can be an early phenomenon and appears to be associated with increased circulating levels of endothelin-1 (ET-1). 50 High ET-1 levels in sepsis are inversely correlated to RV function. A proposed mechanism for RVD in sepsis is increased PVR due to endothelial dysfunction and altered vaso-reactivity, despite systemic vasodilatation. (SVR). 26, 50, 51 M A N U S C R I P T
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DIAGNOSIS OF ACUTE RIGHT VENTRICULAR DYSFUNCTION
Hemodynamic Monitoring
Standard hemodynamic monitoring can provide direct and indirect evidence suggesting the development of acute RVD. It is important to identify and diagnose patients with RVD early, so that interventions aimed at reducing the sequelae may be initiated.
Arterial line monitoring can detect the development of pulse pressure variation (PPV) and allows real-time blood pressure monitoring. PPV refers to dynamic changes of arterial pulse pressure (systolic blood pressure -diastolic blood pressure) induced by mechanical ventilation which can be derived from the arterial pressure waveform analysis and is thought to predict fluid responsiveness. In the context of low tidal volumes and a low pulmonary compliance state such as ARDS, the presence of PPV may signify either volume responsiveness or elevated RV afterload. [52] [53] [54] Of note, for the assessment of PPV to be valid the patient must not be spontaneously breathing, and must be receiving an appropriate controlled tidal volume and be in a regular heart rhythm. If the patient is deemed to be potentially volume responsive, a volume challenge may be given that will both confirm hypovolemia and subsequently improve RV outflow. If the PPV is due to elevated RV afterload (and not secondary to reduced RV preload), a fluid challenge will not reduce the PPV and may in fact worsen RV outflow. In such cases PPV cannot be used as a reliable predictor of fluid responsiveness. However, in patients with elevated PPV who are 'fluid-unresponsive' RVD due to elevated RV afterload should be suspected and investigated promptly with echocardiography. 
Pulmonary Artery Catheter (PAC)
The traditional method of diagnosing RVD was to use a PAC. Given the potential risks of placement and development of less invasive methods of investigating cardiac function, the use of a PAC is now much less common. 57 If a PAC is placed, then the usual findings suggestive of RVD include an elevated CVP (greater than 20mmHg), a CVP greater than pulmonary artery occlusion pressure, and a low cardiac index (< 2.0 L/min/m 2 ) and mixed-venous oxygen saturation (SvO 2 < 55%).
The pulmonary vascular resistance is usually elevated in ARDS. 22 In addition, a PAC can be used to estimate the trans-pulmonary gradient (mean PA pressure -pulmonary artery occlusion pressure) which is also a marker of pulmonary vascular dysfunction which better estimates the resistance of the pulmonary vasculature in ARDS where West zones 1 and 2 can be abnormally extended due to increased transpulmonary pressure. There is a lack of data demonstrating the links between the rate of change in PVR and its implications for the management and prognosis of patients with ARDS. A potentially novel approach for these patients would be the use of pulmonary vasodilators early in the course of ARDS and testing of the hypothesis that this strategy might improve clinical outcomes.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Echocardiography
The availability of and experience with critical care echocardiography has increased exponentially over the past decade. Now echocardiography is generally readily available and accessible in the ICU. Lhe´ritier et al showed that TEE is superior to TTE for diagnosing RVD in mechanically ventilated patients with moderate to severe ARDS. The authors found that using TEE as a reference the sensitivity of TTE for diagnosing RVD in ARDS was only 60% (95% CI 41-77% can be determined on parasternal short axis and apical four chamber views.
Quantitative assessment of RV function can be performed by several methods. TAPSE can be obtained routinely and correlates well with RV function 12, 15, 16, 58 Interpretation of the TAPSE has two potential pitfalls however, it assumes the single segment represents the function of the entire RV, and its measurement is angle dependent. 
Advanced Cardiac Imaging and Biomarkers
Currently there is limited role for advanced cardiac imaging such as cardiac computed tomography (CT) or magnetic resonance imaging (MRI). MRI is hindered by its availability and also the need for low heart rates to enable appropriate gating and study acquisition (this is often technically difficult with critically ill patients). Attempts to demonstrate cardiac CT's ability to predict RV failure have been largely unsuccessful to date. 64, 65 Limited data exists on the role of BNP in the prognostication of ARDS patients with RVD. In contrast, a recent study looking at patients with moderate to severe ARDS demonstrated that an elevated troponin, in conjunction with echo findings of RVD, identified a high-risk subgroup with elevated mortality.
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TREATMENT
The treatment of RV dysfunction can be divided into several physiological targets including optimization of RV preload, increasing RV contractility, and reducing RV afterload. Extracorporeal life support (veno-venous or veno-arterial extracorporeal membrane oxygenation (ECMO), extracorporeal CO 2 removal (ECCO 2 R)) may be considered as rescue therapy in refractory cases of ARDS and RVF.
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Optimization of RV preload
Meticulous management of volume status is crucial for the failing RV, as both low and high filling pressures may result in reduced CO. In patients where hypovolemia is suspected volume loading may increase CO. 66 This must be done cautiously as elevated pulmonary pressures (mean PAP greater than 30 mmHg), as seen in ARDS, may prevent a resultant increase in RV contractility and CO. 30 Excessive volume loading inhibits stroke volume by altering the geometry of the RV resulting in RV dilatation, ventricular interdependence, and impaired LV diastolic compliance. 67 RV dilatation may also cause increased tricuspid regurgitation and right sided venous congestion. A 'mini-fluid challenge' (100 ml of colloid or crystalloid fluid over 1 minute) has been shown to predict fluid responsiveness in patients with circulatory failure receiving low tidal volume ventilation and may be a safer, yet rational approach in patients with suspected RVD as a small rise in cardiac filling pressures may lead to a greater increase in stroke volume during administration of a 'mini-fluid bolus' (steep portion of the Frank-Starling curve). 68, 69 When found, the treatment of elevated filling pressures could be instituted in an attempt to restore RV geometry, reduce RV dilation and ventricular interdependence. The use of diuretics is the simplest approach but hemofiltration and renal replacement therapy (CRRT) may be required if renal function is inadequate. However, there is no empirical evidence to support routine use of diuretics or CRRT in ARDS patients with RVF and this recommendation is based on clinical experience only. In addition, over-diuresis or excessive fluid removal on CRRT may rapidly lead to 'under-filling' of the RV (which is pre-load dependent) and decrease in stroke volume.
Increasing RV contractility
Ensuring the RV has an appropriate heart rate and rhythm can be amongst the simplest methods of improving RV contractility. Right atrial contraction contributes up to 40% of RV filling and is of more importance when the RV compliance is poor. Tachyarrythmias can also lead to a reduction in filling time and thus heart rate should be optimized to diastolic filling.
Initiation of vasoactive support can be important not only in improving RV contractility but also in preventing hemodynamic instability. Hypotension can lead to RV ischemia and subsequent further impairment of RV function that can quickly spiral into a vicious cycle. Targeted systemic pressure should be higher than the pulmonary pressure.
Maintenance of an appropriate systemic pressure while not excessively increasing or even decreasing the pulmonary artery pressures (PAPs) are the traits of an ideal vasopressor. Norepinephrine has been shown in both animal models and in man to increase SVR while reducing PAPs. 71, 72 Norepinephrine at high doses was shown to increase PVR over SVR preferentially and thus at high doses should be used cautiously.
Phenylephrine has been shown to not be as effective as norepinephrine, and in certain situations to actually worsen RV function 29 . Vasopressin is also another vasopressor that preferentially increases SVR over PVR and thus can be useful to maintain systemic pressure without worsening RV afterload. At low doses (<0.03 U/min), Vasopressin causes pulmonary vasodilatation, but at higher doses it increases PVR and causes coronary vasoconstriction and should therefore be used with caution. 73, 74 Dobutamine and milrinone are inodilators that provide inotropism and vasodilation of the systemic and pulmonary vasculature. 75, 76 Due to the profound systemic vasodilating capabilities of these agents, systemic hypotension can result and thus they are often need to be paired with a vasoconstrictor. Vasopressin, in contrast to norepinephrine, has been shown to be more beneficial at reducing PAPs. 77 When comparing dobutamine and milrinone, although there are equivalent reductions in PVR and improvements in cardiac output between the agents, there appears to be a greater reduction in SVR and PCWP when using milrinone. 78 Levosimendan, a calcium sensitizing agent with inotropic and M A N U S C R I P T
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18 vasodilatory properties has been shown to improve RV performance in ARDS patients with septic shock. 79 As an inodilator, it could potentially improve RV-pulmonary vascular coupling but it does not have a proven mortality benefit in the treatment of ARDS patients with RVF. 79 Levosimendan is approved for use in Europe but does not have
Food and Drug Administration approval in the United States. The aforementioned inotropic agents should be used with caution as they can cause tachyarrhythmias and hypotension.
Reducing RV Afterload
Reducing RV afterload in ARDS patients with RVD can be achieved through the use of pulmonary vasodilators, reversal and control of precipitating factors (hypoxemia, hypercapnia, acidemia, hypothermia) and 'RV-protective' mechanical ventilation strategies. 28 
Pulmonary Vasodilators
It is strongly recommended that inhaled rather than systemic pulmonary vasodilators are used when systemic hypotension is anticipated. 28 Inhaled NO (iNO) increases intracellular cyclic guanosine monophosphate and has been shown to transiently improve P a O 2 /F i O 2 ratio and CO in ARDS patients with RVD. 80, 81 It is recommended that iNO is used as a short term therapy to improve oxygenation indices in ARDS as it does not improve mortality regardless of ARDS severity and has also been associated with acute kidney injury. 28, 82, 83 Inhaled prostanoids such as prostaglandin-I 2 (prostacyclin, PGI 2 )
and its analogues such as iloprost, reduce PVR and improve RV performance . Use of nebulized iloprost in ARDS patients with pulmonary hypertension has been associated with an improvement in gas exchange without causing hemodynamic instability. 28, 84 Oral sildenafil, a PDE-5 inhibitor has been shown to decrease RV systolic overload and enhances RV performance in ARDS patients with RVD. The use of pulmonary vasodilators should be individualized as they can worsen oxygenation and shunt fraction. 86 Pulmonary vasodilatation early in the course of ARDS, in patients at risk of RVD (eg RVD risk score >2), and its impact on clinical outcomes has not been studied.
'RV-protective' ventilation strategies
Understanding lung-heart clinical crosstalk in ARDS is likely to be of paramount importance, as RVD does occur in patients subjected to lung protective ventilation. The main proposed components of RV-protective ventilation strategy include: 1) minimizing lung stress by limiting plateau and driving pressures; 2) prevention or reversal of pulmonary vasoconstriction by improving oxygenation and strict CO 2 control; and 3) prone position to unload the RV. 44, 87 It has been shown that 'low-stress' ventilation with plateau pressure less than 26-28 cmH 2 O is associated with lower incidence of RVD. 48 Driving pressure (plateau pressuretotal PEEP) has also been associated with mortality and development of RVD in ARDS. 20, 49, 87 It is recommended that plateau pressure is kept < 27cmH 2 O and driving pressure < 18 cmH 2 O. 44 High PEEP recruits collapsed alveoli but can cause overdistension of functional lung areas. Both atelectasis and overdistension result in increased PVR and high RV afterload. The optimal 'RV-protective' PEEP levels (balance between alveolar recruitment and overdistension) and titration of PEEP remain controversial and the effect of 'low-lung stress' ventilation approach on the RV needs to be validated in large RCTs.
Prone ventilation in ARDS can facilitate reduction in RV afterload by recruiting collapsed alveoli without causing overdistension 88 and reducing airway pressure, P a CO 2 , RV enlargement and septal dyskinesia. 89 A multi-center RCT (PROSEVA) showed a mortality benefit in patients with severe ARDS who were ventilated in the prone position. 4 In addition, the prone group had a lower incidence of cardiac arrest (6.8 vs 13.5%, p<0.05) and shock (14. Normocapnia in ARDS can be challenging to achieve with conventional mechanical
Extracorporeal Life Support (ECLS)
ventilation. An increase in mechanically triggered mandatory breaths can cause increased auto-PEEP, worsening hypercapnia and RVD. 44 Extracorporeal CO 2 removal (ECCO 2 R) devices can be used as adjuncts to invasive mechanical ventilation and could potentially help preserve or restore optimal RV-arterial coupling and prevent RV failure in ARDS patients. 92 Experimental evidence suggests that ECCO 2 R facilitates protective ventilation, reduces minute ventilation by 50% and improves RV function. 
